摘要
胰岛素类似物因其分子结构及代谢特点更符合妊娠期糖代谢的特点,可以更安全、有效地降低妊娠期高血糖,然而部分胰岛素类似物妊娠期应用的安全性和有效性尚不明确。目前我国批准用于妊娠期的胰岛素类似物仅有门冬胰岛素、赖脯胰岛素和地特胰岛素。对于在妊娠期使用或继续使用未经批准用于孕妇的胰岛素类似物等情况,临床医生应根据已发表的临床安全性数据权衡调整用药。本文就速效胰岛素类似物、长效胰岛素类似物和双胰岛素类似物在妊娠期使用的安全性及研究进展进行综述,旨在为临床上妊娠期胰岛素类似物的选择及建议提供参考。
Insulin analogues can reduce gestational hyperglycemia more safely and effectively because their molecular structure and metabolic characteristics are more consistent with the characteristics of gestational glucose metabolism.However,the safety and effectiveness of some insulin analogues in pregnancy remain unclear.At present,only a few insulin analogues,insulin aspart,insulin lispro and insulin detemir,have been approved for use during pregnancy in China.As for misuse or off-label insulin analogues during pregnancy,clinicians should make adjustments based on published clinical safety data.In this review,the safety and progress in the management of gestational hyperglycemia with rapid-and long-acting insulin analogues and insulin degludec/insulin aspart are reviewed to provide reference for insulin therapy during pregnancy.
作者
黄谊红
师少乐
王子莲
Huang Yihong;Shi Shaole;Wang Zilian(Department of Obstetrics,the First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China)
出处
《中华围产医学杂志》
CAS
CSCD
北大核心
2022年第10期776-780,共5页
Chinese Journal of Perinatal Medicine
基金
国家自然科学基金(81771606)
国家重点研发计划(2021YFC2700700)。
